Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF 73 EV-to-EBITDA is 6.61 as of Jul. 23, 2026, which is 39% below its 10-year median of 10.80. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 743 Drug Manufacturers companies, Astellas Pharma ranks better than 75.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Astellas Pharma's enterprise value is $25,577 Mil.
Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $3,869 Mil. Therefore, Astellas Pharma's EV-to-EBITDA for today is 6.61.
The historical rank and industry rank for Astellas Pharma's EV-to-EBITDA or its related term are showing as below:
ALPMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9 Med: 10.8 Max: 24.63
Current: 6.7
During the past 13 years, the highest EV-to-EBITDA of Astellas Pharma was 24.63. The lowest was 5.90. And the median was 10.80.
ALPMF's EV-to-EBITDA is ranked better than 75.91% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.02
vs ALPMF: 6.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Astellas Pharma's PE Ratio (TTM) for today is calculated as:
Astellas Pharma's share price for today is $12.85.
Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.073.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Astellas Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's EV-to-EBITDA falls into.
Astellas Pharma's current Enterprise Value is $25,577 Mil.
Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,869 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a EV-to-EBITDA of 6.61 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Astellas Pharma. This is 39% below median its historical median of 10.80. Over the past decade, Astellas Pharma's EV-to-EBITDA has ranged from 5.90 to 24.63. According to the industry distribution chart, Astellas Pharma ranks #179 out of 743 companies in the Drug Manufacturers industry, placing it in the top 24.1%.
Is Astellas Pharma's EV-to-EBITDA too high?
Astellas Pharma's current EV-to-EBITDA of 6.61 is 39% below median its 10-year median of 10.80. Over the past 10 years, this metric has ranged from a low of 5.90 to a high of 24.63. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. Astellas Pharma's value of 6.61 is 49.2% below this industry median. Based on the distribution chart, Astellas Pharma ranks #179 out of 743 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #179 out of 743 companies for EV-to-EBITDA. This places Astellas Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Astellas Pharma's value of 6.61 is 49.2% below this benchmark. Historically, Astellas Pharma's own EV-to-EBITDA has ranged from 5.90 to 24.63 over the past decade. While the company's 10-year median is 10.80 vs. the industry median of 13.02, Astellas Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current EV-to-EBITDA of 6.61 is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Astellas Pharma. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current EV-to-EBITDA is 6.61, which is 39% below median its own 10-year median of 10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current EV-to-EBITDA is 6.61, which is 39% below median its 10-year median of 10.80 and 49.2% below the Drug Manufacturers industry median of 13.02. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current EV-to-EBITDA is 6.61 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
EV-to-EBITDA: 6.61 (39% below median its 10-year median of 10.80)
GF Value™: $14.18 vs. price of $12.85 (9.4% below fair value)
Industry Position: 49.2% below the Drug Manufacturers median (#179 of 743)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
